178.28
-0.295(-0.17%)
Currency In USD
| Previous Close | 178.57 |
| Open | 178.69 |
| Day High | 179.79 |
| Day Low | 177.96 |
| 52-Week High | 212 |
| 52-Week Low | 86.55 |
| Volume | 58,229 |
| Average Volume | 438,334 |
| Market Cap | 5.74B |
| PE | -110.73 |
| EPS | -1.61 |
| Moving Average 50 Days | 177.38 |
| Moving Average 200 Days | 152.49 |
| Change | -0.3 |
If you invested $1000 in iRhythm Technologies, Inc. (IRTC) since IPO date, it would be worth $6,843.57 as of December 31, 2025 at a share price of $178.275. Whereas If you bought $1000 worth of iRhythm Technologies, Inc. (IRTC) shares 5 years ago, it would be worth $751.55 as of December 31, 2025 at a share price of $178.275.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
iRhythm Technologies to Present at the 44th Annual J.P. Morgan Healthcare Conference
GlobeNewswire Inc.
Dec 29, 2025 9:30 PM GMT
SAN FRANCISCO, Dec. 29, 2025 (GLOBE NEWSWIRE) -- iRhythm Technologies, Inc. (NASDAQ:IRTC), a leading digital health care company focused on creating trusted solutions that detect, predict, and prevent disease, announced today that the company will
New Data at the Asia Pacific Heart Rhythm Society (APHRS) 2025 Highlight the Performance of iRhythm’s Zio Long-Term Continuous Monitoring in an Asian Population
GlobeNewswire Inc.
Nov 21, 2025 1:10 PM GMT
iRhythm Technologies presented new data during the joint Asia Pacific Heart Rhythm Society (APHRS) and Japan Heart Rhythm Society (JHRS) scientific sessions.Large-scale analysis of more than 400,000 patients1 supports the consistency and generalizabi
iRhythm Technologies Announces Publication of Large-Scale Study in Heart Rhythm and New Data Presented at AHA Scientific Sessions 2025
GlobeNewswire Inc.
Nov 11, 2025 1:05 PM GMT
Real-world data across more than 1 million patients published in Heart Rhythm show that 24–48-hour monitoring can miss actionable arrhythmias and highlights the value of iRhythm’s Zio® long-term continuous monitoring (LTCM)– even in patients with fre